Aaron S Kelly1,2, Claudia K Fox3. 1. Department of Pediatrics, University of Minnesota Masonic Children's Hospital, University of Minnesota Medical School, 420 Delaware St. S.E., MMC 715, Minneapolis, MN, 55455, USA. kelly105@umn.edu. 2. Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA. kelly105@umn.edu. 3. Department of Pediatrics, University of Minnesota Masonic Children's Hospital, University of Minnesota Medical School, 420 Delaware St. S.E., MMC 715, Minneapolis, MN, 55455, USA.
Abstract
PURPOSE OF REVIEW: This review provides a rationale for the use of pharmacotherapy in pediatric weight management, summarizes results of some of the key pediatric clinical trials of approved and "off-label" obesity medications, introduces new options in the pediatric pipeline, and offers a glimpse into the future of pediatric obesity medicine. RECENT FINDINGS: Despite the need for adjunctive treatments to enhance the outcomes of lifestyle modification therapy among youth with obesity, none of the obesity medications evaluated to date have been shown to meaningfully reduce BMI or cardiometabolic risk factors. Promising medications recently approved for the treatment of obesity in adults will soon be tested in pediatric trials, offering hope that new therapeutic options will soon be available. As new medications are approved to treat pediatric obesity, it will be important to evaluate the safety and efficacy of combination pharmacotherapy and investigate predictors of response. Application of precision medicine approaches to the field of pediatric obesity management will improve the long-term outlook for the tens of millions of youth afflicted with this serious and recalcitrant disease.
PURPOSE OF REVIEW: This review provides a rationale for the use of pharmacotherapy in pediatric weight management, summarizes results of some of the key pediatric clinical trials of approved and "off-label" obesity medications, introduces new options in the pediatric pipeline, and offers a glimpse into the future of pediatric obesity medicine. RECENT FINDINGS: Despite the need for adjunctive treatments to enhance the outcomes of lifestyle modification therapy among youth with obesity, none of the obesity medications evaluated to date have been shown to meaningfully reduce BMI or cardiometabolic risk factors. Promising medications recently approved for the treatment of obesity in adults will soon be tested in pediatric trials, offering hope that new therapeutic options will soon be available. As new medications are approved to treat pediatric obesity, it will be important to evaluate the safety and efficacy of combination pharmacotherapy and investigate predictors of response. Application of precision medicine approaches to the field of pediatric obesity management will improve the long-term outlook for the tens of millions of youth afflicted with this serious and recalcitrant disease.
Entities:
Keywords:
Pediatric obesity; Pharmacotherapy; Weight loss
Authors: Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich Journal: Lancet Date: 2010-07-29 Impact factor: 79.321
Authors: Claudia K Fox; Alexander M Kaizer; Kyle D Rudser; Brandon M Nathan; Amy C Gross; Muna Sunni; M Jennifer Abuzzahab; Betsy L Schwartz; Seema Kumar; Anna Petryk; Charles J Billington; Justin R Ryder; Aaron S Kelly Journal: Obesity (Silver Spring) Date: 2016-11-03 Impact factor: 5.002
Authors: Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding Journal: N Engl J Med Date: 2015-07-02 Impact factor: 91.245
Authors: Aaron S Kelly; Marsha D Marcus; Jack A Yanovski; Susan Z Yanovski; Stavroula K Osganian Journal: Int J Obes (Lond) Date: 2018-10-03 Impact factor: 5.095
Authors: Christine B San Giovanni; Brooke Sweeney; Joseph A Skelton; Megan M Kelsey; Aaron S Kelly Journal: J Clin Endocrinol Metab Date: 2021-06-16 Impact factor: 5.958
Authors: Y E Lentferink; M P van der Aa; E G A H van Mill; C A J Knibbe; M M J van der Vorst Journal: Nutr Diabetes Date: 2018-09-10 Impact factor: 5.097
Authors: Michelle I Cardel; Mark A Atkinson; Elsie M Taveras; Jens-Christian Holm; Aaron S Kelly Journal: JAMA Pediatr Date: 2020-06-01 Impact factor: 16.193